Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Axovant CEO David Hung Abruptly Exits, COO and Several Directors Also Resign February 11, 2018 A Novel, Quantitative Immunohistochemistry Method Enabled By BioGenex, Inc. IHC System February 16, 2017 FDA Calls BioMarin's Hemophilia A Drug a Breakthrough October 25, 2017
A Novel, Quantitative Immunohistochemistry Method Enabled By BioGenex, Inc. IHC System February 16, 2017